Question · from the living review of Antimicrobial Resistance Novel Antibiotics →

Is it true that carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA) represent the highest-priority critical threats to human health as designated by the WHO and CDC, with clinical mortality rates of 40-70% in bloodstream infections?

Established updated weekly · as of

Priors rates this Established — 92 out of 100, updated weekly. Yes — this looks well established. On the claim that carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA) represent the highest-priority critical threats to human health as designated by the WHO and CDC, with clinical mortality rates of 40-70% in bloodstream infections, its four-agent AI review panel weighs 7 primary peer-reviewed studies.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Antimicrobial Resistance Novel Antibiotics review.

Related Infectious Disease questions

Is it true that antimicrobial resistance is responsible for approximately 1.27 million deaths globally per year as a direct cause, with an additional 3.7 million deaths attributable, making it among the leading infectious causes of global mortality? → Is it true that antimicrobial stewardship programmes (ASPs) in hospital settings reduce inappropriate antibiotic use, length of stay, and Clostridioides difficile infection rates without increasing mortality, as demonstrated in multiple systematic reviews and implementation studies? → Is it true that ceftazidime-avibactam is effective against KPC- and OXA-48-producing Enterobacterales and is superior to colistin-based regimens for carbapenem-resistant infections, but lacks activity against metallo-beta-lactamase (MBL)-producing organisms (NDM, VIM, IMP)? → Is it true that extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have reached endemic prevalence in community and hospital settings globally, with ESBL-E. coli rates exceeding 10% in most European countries and 50% in parts of Asia and sub-Saharan Africa? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.